Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer

Inclusion Criteria: * Minimum age 18 years * Signed informed consent form * Confirmed diagnosis of ovarian cancer except low grade serous, clear cell and mucinous histology * Where patients are treatment naïve, patients need to have disease stage FIGO (International Federation of Gynecology and Obstetrics) III or FIGO IV. * Patient is expected to receive primary chemotherapy/maintenance after initial surgical debulking or a further line of systemic therapy in the relapsed setting according to treatment guidelines * Feasibility of collecting malignant ascites and/or pleural effusion during either primary debulking surgery or a routine drainage procedure prior to initiation of the first or next line of systemic therapy * ECOG (Eastern Cooperative Oncology Group) stage 0-2 Exclusion Criteria: * Previously study participation * Known or suspected HIV or active Hepatitis B and/or C infection or active COVID-19 infection * Anticancer treatment or radiation therapy of the region which is to be drained or biopsied within the last 4 weeks * Patient unfit or not willing to receive any further systemic treatment * Patient is treated with therapeutics not tested in the assay - with the exception of anti-VEGF (Vascular endothelial growth factor) therapy * Known pregnancy * Sample quality criteria are not met (at least 250ml of ascites available, no signes of bacterial superinfection, no additives, at least 1% EpCAM (Epithelial Cell Adhesion Molecule) positive cells, viability at least 60%)